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Abstract
Background: The purpose of this study was to identify early features of lamin A/C gene mutation related dilated
cardiomyopathy (DCM) with cardiovascular magnetic resonance (CMR). We characterise myocardial and functional
findings in carriers of lamin A/C mutation to facilitate the recognition of these patients using this method. We also
investigated the connection between myocardial fibrosis and conduction abnormalities.
Methods: Seventeen lamin A/C mutation carriers underwent CMR. Late gadolinium enhancement (LGE) and cine
images were performed to evaluate myocardial fibrosis, regional wall motion, longitudinal myocardial function,
global function and volumetry of both ventricles. The location, pattern and extent of enhancement in the left
ventricle (LV) myocardium were visually estimated.
Results: Patients had LV myocardial fibrosis in 88% of cases. Segmental wall motion abnormalities correlated
strongly with the degree of enhancement. Myocardial enhancement was associated with conduction abnormalities.
Sixty-nine percent of our asymptomatic or mildly symptomatic patients showed mild ventricular dilatation, systolic
failure or both in global ventricular analysis. Decreased longitudinal systolic LV function was observed in 53% of
patients.
Conclusions: Cardiac conduction abnormalities, mildly dilated LV and depressed systolic dysfunction are common
in DCM caused by a lamin A/C gene mutation. However, other cardiac diseases may produce similar symptoms.
CMR is an accurate tool to determine the typical cardiac involvement in lamin A/C cardiomyopathy and may help
to initiate early treatment in this malignant familiar form of DCM.
Background
Dilated cardiomyopathy (DCM) is a major cause of
heart failure and sudden cardiac death. About one third
of DCM cases are familial. During the past few decades,
several DCM disease genes have been identified, many
of them limited to individuals or families [1-3]. The
lamin A/C gene (LMNA) is so far the most significant
disease gene for DCM. It has been estimated that
LMNA mutations cause up to 10% of familial DCM.
The penetrance of the LMNA mutations causing cardio-
myopathy is nearly complete [4]. The gene resides on
chromosome 1q21.2-q21.3. By alternative splicing, it
codes for lamins A and C, proteins found in the nuclear
lamina. LMNA mutations may also cause a variety of
other clinical entities such as neuromuscular syndromes,
lipodystrophy or premature aging disease, i.e. progeria.
We have previously described several LMNA mutations
among Finnish DCM patients [2,3].
Carriers of LMNA mutations causing cardiomyopathy
should be recognised at an early stage so that regular car-
diologic follow-up can be arranged; affected individuals
have a high risk of sudden cardiac death or severe heart
failure by middle age [5]. However, most of the patients
are asymptomatic or only have mild symptoms for many
years, and diagnosis is therefore difficult. Moreover, the
serious nature of LMNA-related cardiomyopathy is easily
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(LV) dilatation is typically mild at the beginning, and it
may remain so even later on although the LV ejection
fraction may be very low. In other words, LMNA muta-
tions may cause DCM, or cardiomyopathy with decreased
systolic function, combined with LV dilatation that is too
mild to fulfil the criteria of DCM. The earliest cardiac
finding in cardiomyopathy caused by a LMNA mutation is
usually conduction system disease, associated with atrial
or ventricular arrhythmias, atrioventricular (AV) conduc-
tion abnormalities and myocardial dysfunction [6].
Echocardiography is regarded as the standard method
to clinically study DCM; however, cardiovascular mag-
netic resonance (CMR) plays an important role in the
characterisation and risk stratification of patients with
DCM. Late gadolinium enhancement (LGE) CMR with
standard cine-imaging is an accurate and reproducible
method both to demonstrate myocardial fibrosis and to
measure wall thickness as well as global and regional
function of both ventricles [7,8].
The main purpose of this study was to characterise
myocardial fibrosis, regional wall motion abnormalities,
ventricular dilatation, longitudinal LV systolic function
and global function with LGE CMR in asymptomatic or
mildly symptomatic carriers of LMNA mutations caus-
ing DCM. In addition, we investigated the possible asso-
ciation between the localisation of myocardial fibrosis
and the conduction abnormalities documented with
electrocardiography (ECG).
Methods
Study patients
LMNA mutation carriers
The LMNA mutations had originally been identified in
DCM patients who participated in an earlier molecular
genetic study of DCM carried out in collaboration
between the Helsinki University Hospital and the Uni-
versity of Kuopio [2,3]. The subjects in the current
study, recruited from the families of these DCM
patients, were carriers of an LMNA mutation. The study
group comprised seventeen subjects (eight men and
nine women, mean age 36 ± 12, 39 ± 18 years, body
surface area (BSA) 1.8 ± 0.2 m
2) recruited for this study
between 2004 and 2008. Each subject was a heterozy-
gote for one mutation. A summary of the mutations,
symptoms and ECG findings are presented in Table 1.
The clinical evaluation of the subjects comprised hospi-
tal records, clinical examination, venous blood samples,
12-lead ECG, echocardiography and CMR. CMR was
performed during the first visit.
All participants gave written informed consent. The
project was approved by the local institutional ethics
committee.
CMR
CMR was performed with a 1.5 T MR imager (Avanto;
Siemens, Erlangen, Germany) using a multi-channel
body-array coil as a receiver. Breath-hold cine CMR was
performed using retrospectively electrocardiographically
gated segmented true fast imaging with steady-state free
precession (SSFP). Cine MR images were obtained in
vertical and horizontal long-axis, and a stack of images
in short-axis plane covering both ventricles was
acquired. The imaging parameters were TR/TE 3.0/1.6
msec, flip angle 52 degrees, 256 × 256 matrix, 240 ×
340 mm field of view. Slice thickness was 6 mm and
interslice gap 20%. The temporal resolution was 42-49
msec.
Five to fifteen minutes after the injection of a contrast
agent (gadoterate meglumine, Dotarem
® 0.1 mmol/kg)
LGE images were acquired in the same views as for cine
images, using inversion recovery turbo fast-low angle
shot (FLASH). The imaging parameters were TR/TE
2.58/2.3 msec, flip angle 50 degrees, 256 × 256 matrix,
240 × 340 mm field of view. Slice thickness was 8 mm
and interslice gap 0%. Inversion time was optimised for
each measurement to null the signal intensity of normal
myocardium (240-360 msec).
Image analysis
The images were analysed in consensus by two experi-
enced (> 10 years experience) cardiac radiologists (SK,
MH). In each patient, the three LV short axis sections
were divided into 17 segments according to American
Heart Association (AHA) guidelines [9]. The planimetry
of enhancing area was calculated within each segment.
The segmental extent of enhancement on LGE images
was graded using the following score: 0 = no enhance-
ment, 1 = 1-25% enhancement, 2 = 26-50% enhance-
ment, 3 = 51-75% enhancement, 4 = 76-100%
enhancement. Right ventricle (RV) enhancement was
also determined from the LGE images.
On the cine images, segmental wall motion was
visually assessed and scored as 1 = normal, 2 = hypoki-
nesia, 3 = akinesia and 4 = dyskinesia.
Measurement of volumes and ejection fraction of both
ventricles were segmented semi-automatically by track-
ing the endocardial borders of both ventricles with a
segmentation tool developed for this purpose [10].
To assess longitudinal LV systolic function, mitral
annular displacement (MAD) was measured as the dif-
ference (between end-diastole and end-systole) of the
distance from apex to the lateral and septal sites of the
mitral annulus in the horizontal long-axis view, and
apex to the anterior and inferior sites in the vertical
long-axis view. The mean value of MAD at all four sites
was then calculated.
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Statistical analysis was performed using NCSS version
2007 software. Chi-Square test and Fisher’sE x a c tt e s t
were used to calculate for correlation between the per-
centage of LGE and wall motion abnormalities. Volu-
metric results of both ventricles were compared to
normal values published earlier by Maceira et al [11,12]
whose cine sequence technique (SSFP), protocol as well
as volumetric analysis were comparable to those used in
our study. Relationships between MAD and EF as well
as MAD and percentage of LGE were assessed using
Spearman Correlations test. Correlation between con-
duction defects and myocardial fibrosis was calculated
using t-test.
Results
O u to f1 7p a t i e n t s ,1 5e x h i b i t e dL G E .A m o n gt h et o t a l
of 289 segments, LGE was observed in 47 (16%). The
extent of LGE was less than 50% in 36/47 enhanced seg-
ments (Figure 1). In all patients, LGE occurred in the
basal or mid-ventricular septal wall (Figure 2, 3). RV
free wall enhancement was not observed. Thirty three of
the 47 enhanced segments were in the septal area (seg-
ments 2-3, 8-9, 14). The typical pattern of LGE was
linear and mid-myocardial (Figure 4). Diffuse enhance-
ment of LV myocardium was observed in two advanced
cases of the disease. LV wall thickness was normal in all
patients. Abnormal motion was found in 27 segments
(9%). The motion abnormalities were predominantly
located in the basal regions of LV (segments 1-4). There
was hypokinesia in 17 segments and akinesia in 10 seg-
ments. The correlation between the extent of enhance-
ment and abnormal motion was significant (p < 0.001).
Abnormal motion was found in 50% of segments enhan-
cing 26-50% and in all segments if the enhancement was
over 50% (Table 2).
All patients with conduction abnormalities (11 with an
AV conduction defect and two with a widened QRS com-
plex) and two with atrial fibrillation showed enhancement
of the basal and mid-ventricular septum. Conduction
abnormalities correlated significantly with presence of
LGE in the LV septum (p = 0.01). Four patients had a nor-
mal ECG recording, and two of them had enhancement of
the basal septum. Table 3 summarises the ECG abnormal-
ities in relation to the enhanced segments and regional
wall motion abnormalities.
A volumetric analysis of one female subject was
excluded because of poor cine image quality due to
Table 1 The clinical characteristics of LMNA mutation carriers
LMNA
carrier
Gender
(male/
female)
Age
(years)
Mutation Symptoms Cardiac medication Rhythm PR
(upper
limit 200
ms)
QRS
(upper
limit100
ms)
q-waves,
low r-
waves
1 M 42 ser143pro vertigo ACE-blocker fa - 158 V1-3 QS
2 F 54 ser143pro dyspnea
extrasystolia
none sr 276 124 no
3 F 30 ser143pro none none sr 236 96 no
4 M 32 ser143pro none none sr 176 112 no
5 M 18 ser143pro palpitation none sr 176 96 no
6 F 18 ser143pro none none sr 164 108 no
7 F 29 ser143pro palpitation none sr 182 92 no
8 M 39 T1085Xdeletion none none sr 322 106 no
9 M 25 ala132pro paroxysmal
flutter
warfarin, bisoprolol sr 176 112 no
10 F 52 ala132pro extrasystolia none sr 276 92 no
11 M 29 arg190trp palpitation none sr 160 100 no
12 F 32 arg190trp palpitation none sr 140 84 no
13 F 64 arg190trp vertigo warfarin, bisoprolol, digoxin fa - 84 Low r-waves
V1-4
14 M 58 arg190trp dyspnea
NYHA 2
warfarin, AT-receptor blocker, diuretic,
betablocker
sr 208 100 QS V1
15 M 43 ser143pro none none sr 328 90 no
16 F 35 ser143pro extrasystolia none sr 224 76 no
17 F 39 ser143pro none none sr 254 114 QS V1-2
This table demonstrates patients age, gender, type of lamin A/C mutation, symptoms, medications, heart rhythm and possible abnormalities in ECG (prolonged
PR interval, widened QRS complex or presence on q-waves or low t-waves).
NYHA = New York Heart Association classification; sr = sinus rhythm, fa = atrial fibrillation.
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standardised normal values published earlier by Maceira
et al [8,9], ventricular volumes and systolic function
were preserved in five patients. Minor systolic dysfunc-
tion without ventricular dilatation was observed in three
patients (LV dysfunction in one patient and dysfunction
of both ventricles in two patients). Mild LV dilatation
without systolic dysfunction was observed in four
patients, two of whom also had a slightly dilated RV. A
dilated LV and systolic dysfunction was observed in four
patients, three of whom also had RV dysfunction, and
one female subject had RV dilatation without dysfunc-
tion. Table 4 summarises the global ventricular func-
tions and ejection fractions for each of the 16 patients.
Longitudinal LV systolic function was decreased in
nine patients when compared to normal values pub-
lished by Nikitin et al [13]. Decreased MAD was
observed in eight patients with decreased EF, three
patients (18%) with normal EF showed longitudinal LV
systolic dysfunction (Table 3).
MAD was significantly lowered when EF was
decreased (p < 0.03) (Figure 5). MAD correlated signifi-
cantly with percentage of myocardial LGE (p < 0.01)
(Figure 6).
Discussion
The present study demonstrates that 88% of asympto-
matic or mildly symptomatic carriers of LMNA muta-
tions causing cardiomyopathy had typical myocardial
fibrosis, predominantly in the mid-myocardium of the
basal septum. This was observed in all individuals with
an AV conduction defect. The pattern of enhancement
was typically linear and less than 50% of the area of the
segment. Enhancement was associated with wall motion
abnormalities at LV basal segments, where the degree of
enhancement had a significant correlation with
decreased motion. Minor systolic dysfunction without
ventricular dilatation, preserved systolic function with
mild LV dilatation or systolic dysfunction with mild
dilatation of LV, or of both ventricles, was observed in
69% of LMNA mutation carriers. In our patients as an
early marker of the disease longitudinal LV systolic
function was decreased in nine patients when compared
to normal values [13]. In addition, we found that LV EF
as well as percentage of myocardial fibrosis correlated
significantly with abnormal MAD.
Early studies show that even a very small amount of
myocardial scar tissue is visible with routine LGE CMR
sequences [14]. Myocardial diseases have typical
enhancement patterns on the basis of their characteristic
pathology [15]. In previous studies, about one third of
DCM patients have demonstrated mid-myocardial linear
enhancement on LGE CMR in a non-coronary distribu-
tion, predominantly in the LV basal and mid-ventricular
septum [8,16-19]. However, Ebeling Barbier et al have
documented that 30% of elderly volunteers without or
with minimal coronary artery disease showed myocardial
LGE, but mostly inferolateral region of the LV. On the
other hand, Breuckmann et al found that 12% of mara-
thon runners had LGE. Subendocardial and transmural
LGE pattern was found in five marathon runners, but
Figure 1 The extent of enhancement (%) in abnormal
myocardial segments. The percentage of late gadolinium
enhancement in involved myocardial segments (n = 47). The extent
of enhancement was under 25% in sixteen (6%) segments. Twenty
(2%) of the segments showed enhancement of 26-50%. Eleven
segments (4%) enhanced over 50% of the area.
Figure 2 Left ventricular segmentation.T h el e f tv e n t r i c l ew a s
divided into 17 segments according to American Heart Association.
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jects [20]. A healthy control group of DCM patients in
study by Zimmerman et al [18] showed no myocardial
LGE. As LGE imaging is widely used as a gold standard
in cardiac research, we did not collect any new data of
healthy subjects [21]. In our study, 88% of LMNA muta-
tion carriers had typical myocardial fibrosis, predomi-
nantly mid-myocardially in the basal septum. High
degree of LGE in our patients may reflect the effect of
these mutations alone and not the effects of Lamin A/C
mutations in general.
Assomull et al reported that mid-wall myocardial fibro-
sis in DCM patients predicted both ventricular tachycar-
dia and sudden cardiac death [17]. Cardiomyopathy
caused by a LMNA mutation has a malignant course and
affected individuals are at high risk of sudden cardiac
death [6]. The earliest cardiac finding is usually conduc-
tion system disease [22]. Raman et al demonstrated mid-
myocardial fibrosis and abnormal LV diastolic function
with LGE CMR in patients with DCM caused by a
LMNA mutation [23]. This is in line with our findings,
the majority of our patients having myocardial scarring
Figure 3 Correlation between enhanced myocardial segments and wall motion abnormalities. Distribution of enhanced segments (a) and
wall motion abnormalities (b) of the left ventricle are shown in bull’s eye plots. Our data demonstrates predominant involvement of fibrosis and
wall motion disturbances in the basal and anteroseptal segments.
Figure 4 Myocardial late gadolinium enhancement (LGE) in the septal region evaluated with cardiovascular magnetic resonance
(CMR). LGE CMR of a 32-year old male with lamin A/C mutation DCM. Four-chamber (a) and short axis (b) views of the heart show typical mid-
myocardial and linear enhancement of the basal septum (arrows).
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areas.
Previous autopsy studies have shown the location of
fibrosis near the region of the conduction system and
this has been postulated to be the cause of the AV
blocks in LMNA-related cardiomyopathies [24,25]. In
consensus, cardiac conduction defects such as a pro-
longed PR interval, a widened QRS complex and atrial
fibrillation correlated with the presence of septal wall
fibrosis and motion abnormalities in our study.
Zimmermann et al concluded that enhancement is a
typical feature on CMR carried out in DCM patients
b u ti td i dn o tc o r r e l a t ew i t hm y o c a r d i a lb i o p s yf i n d i n g s
[18]. Since a biopsy only yields information about the
selected biopsy site the detection of fibrosis with biopsy
can be unsatisfactory due to the mid-myocardial loca-
tion of fibrosis. Whereas LGE imaging can be used to
reliably detect the location and extent of fibrosis, and it
can even be used to offer guidance in biopsy sampling
[26]. Sixty-nine percent of our asymptomatic or mildly
Table 2 Myocardial late gadolinium enhancement (LGE) and movement abnormalities in the left ventricle
Percentage of LGE within the segment Normal movement (%) Abnormal movement (%) Total
No enhancement 240 (99) 2 (1) 242
0-25% 12 (75) 4 (25) 16
26-50% 10 (50) 10 (50) 20
51-75% 0 (0) 6 (100) 6
76-100% 0 (0) 5 (100) 5
total 262 27 289
LGE correlated significantly (p < 0.001) with abnormal movement analyzed in each 17 myocardial segment separately. Abnormal motion (hypokinesia or akinesia)
was documented in 27 segments out of 289 segments. Abnormal motion was found in 50% of segments enhancing 26-50% and in all segments if enhancement
was over 50%.
Table 3 Electrocardiography (ECG) and cardiovascular magnetic resonance (CMR) findings
Patient
gender
Age ECG Enhanced
myocardial
segments
Abnormal
movement
(segments)
LV EDV
ml/m
2
LV ESV
ml/m
2
LV EF
%
RV EDV
ml/m
2
RV ESV
ml/m
2
RV EF
%
MAD
cm
M 42 fa 1-3 2-3 112 84 25 65 49 26 0.73
F 54 DAV 1 2-3 2-3 107 50 53 97 40 59 0.93
F 30 DAV 1 2,8 106 37 65 97 38 61 1.61
M3 2 s r
qrs > 100 ms
2-4 2-3 109 44 60 93 38 59 1.51
M1 8 s r 9 545 53 95 48 49 1.85
F1 8 s r
qrs > 100 ms
2 83 30 64 76 33 55 1.60
F 29 sr 3 80 29 64 75 28 63 1.28
M 39 sinusbrady
DAV 1
2-3 112 41 63 120 54 56 2.13
M 25 sinusbrady
qrs > 100 ms
2-3,7-9 2 117 41 65 123 49 60 1.68
F 52 DAV 1 1-2 76 34 56 63 32 50 1.55
M 29 sr 98 37 62 95 42 56 1.78
F 32 sr 2-3,9 1.32
F 64 fa 2-4,8-9,11-12 2-4 74 36 52 67 37 45 0.97
M 58 DAV 1 1-4,7-10,13-15 1-4,7-15 118 59 50 100 58 41 0.72
M 43 DAV 1 2-3 2-3 117 68 42 71 48 33 1.08
F 35 DAV1 1-2 1-2 73 26 65 61 28 54 1.43
F 39 DAV 1 1-17 88 32 64 75 26 66 1.44
This table demonstrates ECG and CMR findings of lamin A/C dilated cardiomyopathy patients. Type of conduction defect documented with ECG, volumetric and
functional data of ventricles, late gadolinium enhancement and wall motion abnormalities of myocardial segments evaluated with CMR are presented. Abnormal
volumetric and functional values are shown highlighted.
RV = right ventricle, LV = left ventricle, EDV = end diastolic volume, ESV end systolic volume, EF = ejection fraction fa = atrial fibrillation, sr = sinus rhythm, DAV
= atrio-ventricular block, MAD = mitral annular displacement (normal value between 1.5-1.6 cm).
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tation and systolic failure in global analysis. Twelve of
our 17 patients were also participants in the study of
Koikkalainen et al, which determined an amalgam of
parameters calculated from cine images typical for
LMNA mutation carriers [27]. The study also found a
significant difference between the patient and control
group in volumetric and function parameters even in
the early and asymptomatic stage of the disease. Fifty-
three percent of our patients had decreased longitudinal
LV systolic function. LV myocardial contraction and
relaxation are reported to impair first in longitudinal
direction in patients with heart failure [28,29].
Conclusions
In conclusion, in the early stage of DCM caused by a
LMNA gene mutation, AV conduction defects are
common with or without a minor depression in LV sys-
tolic function. Usually the suspicion of DCM caused by
LMNA mutations is based on the presence of conduc-
tion system disturbances in an ECG and by clinical
exclusion of other aetiologies. However, other inflamma-
tory or infiltrative cardiomyopathies may resemble DCM
caused by LMNA mutations. If the typical pattern and
location of myocardial fibrosis, mild LV dilatation and
systolic ventricular dysfunction can be accurately
observed with LGE CMR in the early stage of the dis-
ease, the diagnosis can be confirmed by DNA analyses.
Myocardial scarring is known to provide a substrate for
ventricular dysfunction, conduction abnormalities and
ventricular arrhythmias. The disease is known to have a
malignant course, and the combination of ECG record-
ings and LGE CMR will help to recognise these patients.
LGE CMR can also be used to differentiate between
LMNA-related cardiomyopathy and cardiac sarcoidosis,
both of which can cause AV conduction defects and
arrhythmias. Although no specific medical treatment
exits so far to prevent the development of LMNA-
related cardiomyopathy, sudden cardiac death may be
prevented by a timely placement of a pacemaker or an
implantable cardioverter defibrillator.
LGE CMR is also a reproducible method to monitor
the progression of the disease and therefore we have an
ongoing follow-up study with DE-MRI to obtain further
information about the progression of the familial form
of DCM caused by a LMNA mutation.
Study limitations
We had a limited number of patients, all of them car-
riers of a rare familial form of DCM caused by a LMNA
mutation (14 out of the 17 Lamin A/C mutations in the
population are due to either a ser143pro mutation (n =
Table 4 Left ventricular volumes and function parameters
evaluated with cardiovascular magnetic resonance
Males n = 8 Females n = 8
BSA m
2 1.99 ± 0.20 1.80 ± 0.25
LV EDV ml/m
2 110 ± 9 (64-103) 86 ± 12 (59-99)
LV ESV ml/m
2 52 ± 16 (17-41) 34 ± 4 (17-37)
LV SV ml/m
2 57 ± 15 (42-68) 52 ± 10 (14-37)
LV EF % 52 ± 13 (57-75) 60 ± 0.1 (56-77)
RV EDV ml/m
2 95 ± 20 (60-106) 76 ± 14 (55-92)
RV ESV ml/m
2 48 ± 6 (14-43) 33 ± 5 (12-38)
RV SV ml/m
2 47 ± 20 (38-70) 43 ± 12 (36-60)
RV EF % 47 ± 13 (53-78) 57 ± 7 (54-78)
Left ventricular volumes and function parameters of 16 patients with dilated
cardiomyopathy, who were heterozygotes with one LMNA mutation. Cine
images of one patient were excluded from volumetric analysis for poor image
quality. Normal values are presented within parenthesis.
BSA = body surface area, RV = right ventricle, LV = left ventricle, EDV = end
diastolic volume, ESV = end systolic volume, EF = ejection fraction.
Figure 5 Relationship between mitral annular displacement
(MAD) and Left ventricular ejection fraction (EF). Longitudinal LV
systolic function measured using MAD showed correlation with
decreased EF. Nine patients had decreased MAD (normal value 1.5-
1.6 cm). Three lamin A/C DCM patients with normal EF had
decreased MAD as an early marker of systolic dysfunction.
Figure 6 Relationship between mitral annular displacement
(MAD) and late gadolinium enhancement (LGE). Longitudinal LV
systolic function measured using MAD showed a significant
correlation with a percentage of LGE (fibrosis) in the left ventricle
myocardium. LGE scoring was calculated by summarizing enhanced
LV segments of each patient. LV = left ventricle.
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abnormalities were visually graded as well as the percen-
tage of enhancement in LV segments. As both cine
v o l u m e t r ya n dL G Ei m a g i n ga r ew i d e l yu s e da sg o l d
standards in cardiac research, we did not collect any
new data of healthy subjects. Global volumetric CMR
results and longitudinal systolic function were compared
with previously published normal values obtained from
healthy volunteers.
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